Trending...
- Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field - 114
- Las Vegas Business Leader and Jamaican Native Jo Cato Turns Personal Loss into Purpose
- SecurePII Raises US$3.5M (A$5M) to Unlock AI and Compliance for Voice Data and Expands Global Presence
Placed by a Neurosurgeon at the Time of Resection, GammaTile® Therapy Gives Patients a Head STaRT in the Fight Against Brain Tumors, Delaying Tumor Recurrence
TEMPE, Ariz. - nvtip -- GT Medical Technologies, Inc. today announced its GammaTile® Surgically Targeted Radiation Therapy (STaRT) for patients with brain tumors will be spotlighted at the 2021 CNS Annual Meeting exhibition October 18-20 in Austin, Texas, and at the 15th Tumor Section Satellite Symposium which immediately precedes it October 15-16.
"Neurological surgeons and affiliated healthcare professionals attend these prestigious events to learn about the latest advancements in neurosurgical care," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "We look forward to sharing our valuable data that demonstrates how GammaTile Therapy has significantly improved traditional brain tumor radiation and patient outcomes."
More on nvtip.com
Tumor Section Satellite Symposium
This two-day Symposium features engaging scientific sessions that explore technological advances in neurosurgical neuro-oncology. Attendees will have the opportunity to learn more about GammaTile Therapy in a Lunch Symposium on Saturday, October 16 at 12:15 p.m.
Once a year, thousands of neurosurgeons, physicians, and affiliates from around the globe come together to attend the CNS Annual Meeting to hear about the latest technological improvements in neurosurgical treatment. This will be the first in-person conference since 2019, due to the necessity of a virtual exchange in 2020. This year, attendees can visit GT Medical Technologies at booth 1750 to learn more about GammaTile Therapy.
About GT Medical Technologies, Inc.
More on nvtip.com
Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.
"Neurological surgeons and affiliated healthcare professionals attend these prestigious events to learn about the latest advancements in neurosurgical care," said Matthew E. Likens, president and CEO of GT Medical Technologies, Inc. "We look forward to sharing our valuable data that demonstrates how GammaTile Therapy has significantly improved traditional brain tumor radiation and patient outcomes."
More on nvtip.com
- How AI is Exposing Major Flaws in the Foundation & Structure of Technology, Hardware & the Internet & Phinge's Patented Netverse, App-less Solution
- Realtor Trang Hooser and her husband David Hooser Treat their Team to All-inclusive Weekend
- Revenue Optics Ignites AI Revolution in Industrial Distribution
- Arnica Unveils "Arnie AI" to Secure the Future of AI-Driven Software Development
- Axiros North America Announces New CEO: Gabriel Davidov
Tumor Section Satellite Symposium
This two-day Symposium features engaging scientific sessions that explore technological advances in neurosurgical neuro-oncology. Attendees will have the opportunity to learn more about GammaTile Therapy in a Lunch Symposium on Saturday, October 16 at 12:15 p.m.
- Focus: Neurosurgical Oncology
- October 15-16 | JW Marriott, Austin Texas
- GT Medical Technologies booth 200
- Saturday, October 16, 12:15 PM-1:15 PM: GammaTile® Therapy: Technology and Device Overview
Once a year, thousands of neurosurgeons, physicians, and affiliates from around the globe come together to attend the CNS Annual Meeting to hear about the latest technological improvements in neurosurgical treatment. This will be the first in-person conference since 2019, due to the necessity of a virtual exchange in 2020. This year, attendees can visit GT Medical Technologies at booth 1750 to learn more about GammaTile Therapy.
- October 18-20 Exhibits | Austin Convention Center
- GT Medical Technologies booth 1750
About GT Medical Technologies, Inc.
More on nvtip.com
- CCHR Exposes Harms Behind Today's Mental Health Awareness Campaigns
- Now Is the Right Time: Kaltra Highlights Its Proven Replacement Microchannel Coils
- Netverse AI to Use Less Energy: Phinge's Verified AI & Patented App-Less Platform & Hardware Will Require Less Energy, Due to its Integrated Codebase
- How to Optimize Your Website for AI Search with DeepRank AI
- New Free Science Bingo Cards Help Grade 1 Students Learn Through Play
Driven to overcome the limitations of current treatments for brain tumors and raise the standard of care, a team of brain tumor specialists joined forces and formed GT Medical Technologies with the purpose of improving the lives of patients with brain tumors. Its GammaTile Therapy received FDA 510(k) regulatory clearance for the treatment of all types of recurrent brain tumors and newly diagnosed malignant tumors. Patients receive their course of radiation while going about their daily lives, requiring no additional trips to the hospital or clinic for radiation therapy. GammaTile is available in top brain tumor centers across the United States. For more information or to find a GammaTile center near you, visit https://www.gtmedtech.com/ and follow @GTMedTech on Twitter and LinkedIn.
Source: GT Medical Technologies
Filed Under: Technology
0 Comments
Latest on nvtip.com
- Year-Round Deals for Customers With Square Signs
- SecurePII Raises US$3.5M (A$5M) to Unlock AI and Compliance for Voice Data and Expands Global Presence
- Las Vegas Business Leader and Jamaican Native Jo Cato Turns Personal Loss into Purpose
- Peter Coe Verbica Stands with Rural Families and Horse Owners: "Keep Horses Classified as Livestock"
- The Mobile-First Company Raises $12M to Build Simple, Powerful Software for Small Teams
- Lick Pineapple Flavored Massage Oil Outperforming and Enticing
- Cerberus ODC in Collaboration with NVIDIA Launches All-American AI-RAN Stack, Enabling AI-Native 5G Today and Accelerating the Path to 6G
- National Compliance Firm issues Artificial Intelligence Policy Program for Mortgage Banking
- Pastor Darrell Armstrong Suspends Gubernatorial Campaign And Endorses Mikie Sherrill
- Dr. Johnny Shanks Attends Full Arch Growth Conference 2025
- Offline Asset Protection: NJTRX Implements 98 Percent Cold Storage as Industry Faces 2 Billion USD Losses
- Thousands of Smiles, Millions of Logo Views: RoarFun Brings Emotions Into Premium Retail Spaces with Formula Simulator for Immersive Brand Activation
- Qvarz LLC Expands Global Reach with High-Precision Quartz Cuvettes and Optical Components
- $300 Million Web3 Initiative and ZIGChain Partnership Power $20 Target in Noble Capital Markets Report for SEGG Media (N A S D A Q: SEGG)
- Assent Recognizes Manufacturers for Leading Supply Chain Sustainability Programs
- Phinge's Netverse to Introduce Innovative Prediction Model, Offering Users Enhanced Benefits & Rewards for Volunteered Data Sharing
- Arc Longevity Sells Out Debut Women's Creatine Gummy
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Phinge, Home of Netverse, Through its Extensive Software & Hardware Patent Portfolio, Shows Founder & CEO Robert DeMaio's Vision & Innovation
- OddsTrader Reveals Early Favorites and Best Bets to Win March Madness 2026
